Skip to content
Carbetapentane
Carbetapentane is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
SARS-CoV-2 Interaction
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
coughHP_0012735D003371R05
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05D: Cough suppressants, excl. combinations with expectorants
— R05DB: Other cough suppressants in atc
— R05DB05: Pentoxyverine
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F202617281263
Bipolar disorderD001714EFO_0000289F30.9—21411633
Psychotic disordersD011618F20.81—3619431
DepressionD003863F33.9—112—4
Major depressive disorderD003865EFO_0003761F22—211—4
Anxiety disordersD001008EFO_0006788F41.1——12—3
DeliriumD003693R41.0—111—3
ManiaD000087122F30———213
Schizophrenia spectrum and other psychotic disordersD019967———2—2
Mood disordersD019964EFO_0004247F30-F39—111—2
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Social phobiaD000072861EFO_1001917F40.1—1———1
Cognition disordersD003072—1———1
Conduct disorderD019955EFO_0004216F91—1———1
Attention deficit and disruptive behavior disordersD019958HP_0010865F91.3—1———1
Borderline personality disorderD001883HP_0012076F60.3—1———1
Autistic disorderD001321EFO_0003758F84.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Opioid-related disordersD009293EFO_0005611F111————1
Cardiovascular diseasesD002318EFO_0000319I981————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psychomotor agitationD011595————22
HyperglycemiaD006943HP_0003074R73.9————22
Type 2 diabetes mellitusD003924EFO_0001360E11————22
HyperlipidemiasD006949EFO_0003774E78.5————11
Obsessive-compulsive disorderD009771EFO_0004242F42————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARBETAPENTANE
INNpentoxyverine
Description
1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester is a member of benzenes.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1
Identifiers
PDB—
CAS-ID77-23-6
RxCUI20217
ChEMBL IDCHEMBL73234
ChEBI ID—
PubChem CID2562
DrugBankDB11186
UNII ID32C726X12W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 131 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
13,882 adverse events reported
View more details